Current Prospective of Hypertension Disease and their Future Aspects in Different Stage of Female Health

Vishal Dixit; Anamika; Shivanand Patil

doi:10.55544/jrasb.3.6.8

Authors

Vishal Dixit Research Scholar, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.
Anamika Assistant Professor, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.
Shivanand Patil Professor, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology (SDBIT), Dehradun, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.6.8

Keywords:

Hypertension, Blood Pressure, Female, Gestational, Pregnancy, Menopause

Abstract

Cardiovascular disease is the primary cause of mortality in women. Due to age and worsening of risk factors over the menopausal transition, risk of coronary heart disease events increases in postmenopausal women with diabetes. Randomized studies have conflicted regarding the beneficial impact of estrogen therapy upon intermediate cardiovascular disease markers and events. Therefore, estrogen therapy is not currently recommended for indications other than symptom management. However, for women at low risk of adverse events, estrogen therapy can be used to minimize menopausal symptoms. The risk of adverse events can be estimated using risk engines for the calculation of cardiovascular risk and breast cancer risk in conjunction with screening tools such as mammography. Use of estrogen therapy, statins, and anti-platelet agents can be guided by such calculators particularly for younger women with diabetes. Risk management remains focused upon lifestyle behaviors and achieving optimal levels of cardiovascular risk factors, including lipids, glucose, and blood pressure. Use of pharmacologic therapies to address these risk factors, particularly specific hypoglycemic agents, may provide some additional benefit for risk prevention. The minimal benefit for women with limited life expectancy and risk of complications with intensive therapy should also be considered.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Whelton PK, Carey RM, Aronow WS, Jr. Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2017;138(17):e484–594.

Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al. Antenatal lifestyle advice for women who are overweight or obese: LIMIT randomised trial. BMJ. 2014;348:g1285. 10.1136/bmj.g1285

Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394(10203):1011–21. 10.1016/S0140-6736(19)31282-6

Lardoux H, Gerard J, Blazquez G, Chouty F, Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. Eur Heart J. 1983;4:35–40. Suppl G. 10.1093/eurheartj/4.suppl_G.35

Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(2):138–45. 10.1002/pds.2068

Rezk M, Emarh M, Masood A, Dawood R, El-Shamy E, Gamal A, et al. Methyldopa versus Labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. Hypertens Pregnancy. 2020;39(4):393–8. 10.1080/10641955.2020.1791902

Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol. 1977;84(6):419–26. 10.1111/j.1471-0528.1977.tb12616.x

Nisell H, Lintu H, Lunell NO, Mollerstrom G, Pettersson E. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol. 1995;102(11):876–81. 10.1111/j.1471-0528.1995.tb10874.x

Salama M, Rezk M, Gaber W, Hamza H, Marawan H, Gamal A, et al. Methyldopa versus Nifedipine or no medication for treatment of chronic hypertension during pregnancy: a multicenter randomized clinical trial. Pregnancy Hypertens. 2019;17:54–8. 10.1016/j.preghy.2019.05.009

Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10:CD002252.

Nayak AS, Nachane HB. Risk analysis of suicidal ideations and postpartum depression with antenatal alpha methyldopa use. Asian J Psychiatr. 2018;38:42–4. 10.1016/j.ajp.2018.10.024 [

Webster LM, Myers JE, Nelson-Piercy C, Harding K, Cruickshank JK, Watt-Coote I, et al. Labetalol Versus Nifedipine as Antihypertensive Treatment for chronic hypertension in pregnancy: a Randomized Controlled Trial. Hypertension. 2017;70(5):915–22. 10.1161/HYPERTENSIONAHA.117.09972

Kurtzman JL, Thorp JM Jr., Spielman FJ, Mueller RC, Cefalo RC. Do nifedipine and verapamil potentiate the cardiac toxicity of magnesium sulfate? Am J Perinatol. 1993;10(6):450–2. 10.1055/s-2007-994629

Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol. 1988;159(2):308–9. 10.1016/S0002-9378(88)80072-3

Ales K. Magnesium plus nifedipine. Am J Obstet Gynecol. 1990;162(1):288. 10.1016/0002-9378(90)90867-7

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–241. 10.1093/eurheartj/ehy340

Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev Cardiol. 2015;12(12):718–29. 10.1038/nrcardio.2015.172

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–60. 10.1136/bmj.327.7421.955

Un Nisa S, Shaikh AA, Kumar R. Maternal and fetal outcomes of pregnancy-related Hypertensive disorders in a Tertiary Care Hospital in Sukkur, Pakistan. Cureus. 2019;11(8):e5507.

Liu CM, Cheng PJ, Chang SD. Maternal complications and perinatal outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese women. J Formos Med Assoc. 2008;107(2):129–38. 10.1016/S0929-6646(08)60126-6

Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008;51(4):1002–9. 10.1161/HYPERTENSIONAHA.107.107565

.Adams EM, Macgillivray I. Long-term effect of preeclampsia on blood-pressure. Lancet. 1961;2(7217):1373–5. 10.1016/S0140-6736(61)91196-5

Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol. 1986;155(5):1011–6. 10.1016/0002-9378(86)90336-4

Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart. 1997;77(2):154–8. 10.1136/hrt.77.2.154

Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-term prognosis of hypertension in pregnancy. Hypertens Pregnancy. 2000;19(2):199–209. 10.1081/PRG-100100136

Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C et al. Preeclampsia and Future Cardiovascular Health: a systematic review and Meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2).

Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010;28(4):826–33. 10.1097/HJH.0b013e328335c29a

Ying W, Catov JM, Ouyang P. Hypertensive disorders of pregnancy and future maternal Cardiovascular risk. J Am Heart Assoc. 2018;7(17):e009382. 10.1161/JAHA.118.009382

Scantlebury DC, Kane GC, Wiste HJ, Bailey KR, Turner ST, Arnett DK, et al. Left ventricular hypertrophy after hypertensive pregnancy disorders. Heart. 2015;101(19):1584–90. 10.1136/heartjnl-2015-308098

Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Reckelhoff JF. Postmenopausal hypertension: role of the renin-angiotensin system. Hypertension. 2010;56(3):359–63. 10.1161/HYPERTENSIONAHA.110.152975

Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med (Lausanne). 2021;8:798958. 10.3389/fmed.2021.798958

Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J. 2006;82(968):357–62. 10.1136/pgmj.2005.036053

DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci (Lond). 2011;120(9):357–75. 10.1042/CS20100476

Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35(11):1039–47. 10.1038/hr.2012.138

Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials. 2012;7(1):47–70. 10.2174/157488712799363253

Huikuri HV, Pikkujamsa SM, Airaksinen KE, Ikaheimo MJ, Rantala AO, Kauma H, et al. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation. 1996;94(2):122–5. 10.1161/01.CIR.94.2.122

Tsuji H, Larson MG, Venditti FJ Jr., Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. Framingham Heart Study Circulation. 1996;94(11):2850–5. 10.1161/01.CIR.94.11.2850

Saleh TM, Connell BJ. Role of oestrogen in the central regulation of autonomic function. Clin Exp Pharmacol Physiol. 2007;34(9):827–32. 10.1111/j.1440-1681.2007.04663.x

Yalamudi K. Study of comparison between autonomic dysfunction and Dyslipidemia in healthy postmenopausal women. J Midlife Health. 2017;8(3):103–9.

James GD, Sealey JE, Muller F, Alderman M, Madhavan S, Laragh JH. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl. 1986;4(5):S387–9.

Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1997;95(1):39–45. 10.1161/01.CIR.95.1.39

Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404–11. 10.1210/jc.2003-030242

Casiglia E, Tikhonoff V, Caffi S, Bascelli A, Schiavon L, Guidotti F, et al. Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. J Hypertens. 2008;26(10):1983–92. 10.1097/HJH.0b013e32830bfdd9

Cifkova R, Pitha J, Lejskova M, Lanska V, Zecova S. Blood pressure around the menopause: a population study. J Hypertens. 2008;26(10):1976–82. 10.1097/HJH.0b013e32830b895c

Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669–80. 10.1093/eurheartj/ehn427

Bierer BE, Meloney LG, Ahmed HR, White SA. Advancing the inclusion of underrepresented women in clinical research. Cell Rep Med. 2022;3(4):100553. 10.1016/j.xcrm.2022.100553

Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Hum Hypertens. 1999;13(5):337–42. 10.1038/sj.jhh.1000815

Stimpel M, Koch B, Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998;89(4):271–6. 10.1159/000006799

Fernandez-Vega F, Abellan J, Vegazo O, De Vinuesa SG, Rodriguez JC, Maceira B, et al. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. Kidney Int Suppl. 2002;82:S36–41. 10.1046/j.1523-1755.62.s82.8.x

Stimpel M, Koch B, Weber MA. Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. Maturitas. 1998;30(1):69–77. 10.1016/S0378-5122(98)00037-1

Ikeda H, Inoue T, Uemura S, Kaibara R, Tanaka H, Node K. Effects of Candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms. Hypertens Res. 2006;29(12):1007–12. 10.1291/hypres.29.1007

Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, et al. Hypertension and its treatment in postmenopausal women: baseline data from the women’s Health Initiative. Hypertension. 2000;36(5):780–9. 10.1161/01.HYP.36.5.780

Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33(1):41–50. 10.1046/j.1365-2362.2003.01103.x

Kujala SM, Poyhonen-Alho M, Kaaja RJ. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. Climacteric. 2014;17(4):356–62. 10.3109/13697137.2013.842226

Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77–81. 10.1016/j.amjhyper.2003.08.016

Agabiti-Rosei E, Ambrosioni E, Pirelli A, Stimpel M, Zanchetti A. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug after Menopause. Eur J Clin Pharmacol. 1999;55(3):185–9. 10.1007/s002280050616

Hayoz D, Zappe DH, Meyer MA, Baek I, Kandra A, Joly MP, et al. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. J Clin Hypertens (Greenwich). 2012;14(11):773–8. 10.1111/jch.12004

Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80(8):1438–47.

Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart failure: a prospective cohort study and Meta-analysis. J Am Heart Assoc. 2016;5(8).

Gérard, A., Woolfe, A., Mottet, G., Reichen, M., Castrillon, C., Menrath, V., ... & Brenan, C. (2020). High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nature biotechnology, 38(6), 715-721.

Amjad, M., Gupta, H., & Kumar, R. (2024). Diabetic Retinopathy: Current Understanding, Mechanisms and Treatment Strategies. Journal for Research in Applied Sciences and Biotechnology, 3(2), 252-260.

Sah, S., Kumar, R., Saini, R., & Patil, S. M. (2024). Role of Herbal Essential Oil in Cervical Cancer: A Systematic Review. Journal for Research in Applied Sciences and Biotechnology, 3(5), 59–79.

Kumar, V., Gupta, H., & Kumar, R. (2024). Therapeutic Approaches of Nutraceuticals in Neurological Disorders: A Review. Journal for Research in Applied Sciences and Biotechnology, 3(2), 261-281.

PASWAN, S. K., DHARMENDRA AHUJA, D. L., KUMAR, S., MUZTABA, M., AHMAD, A., Selvakumar, P., ... & KUMAR, R. (2023). Volatile alkaloids and brain disorder investigation of the cognitive and mood effects of Zingiber officinale essential oil with in vitro properties relevant to central nervous system function. Journal of Pharmaceutical Negative Results, 574-589.

Bashir, S., Farooq, Z., Zafar, S., Tufail, T., Ain, H. B. U., Hussain, M., ... & Nyarko, R. O. (2023). Recording Postprandial Glucose Reactions with Potato Starch Structural Improvements. International Journal of Food Science, 2023(1), 1263896.

Nyarko, R. O., Awuchi, C. G., Kumar, R., Boateng, E., Kahwa, I., Boateng, P. O., ... & Saha, P. (2022). Effect of Calotropis Procera Extract on Appetitte, Body Weight & Lipid Profile in Cafeteria Diet Induced Obesity in Experimental Animal. Journal for Research in Applied Sciences and Biotechnology, 1(3), 107-113.

Nyarko, R. O., Kumar, R., Sharma, S., & Chourasia, A. (2022). Ayushmann Roy, and Purabi Saha.". Antibacterial Activity Of Herbal Plant-Tinospora Cordifolia And Catharnthus Roseus, 10-24.

Prajapati, A. K., Sagar, S., & Kumar, R. (2022). Past and Current Prospectives of Herbal Product for Skin Care. Journal for Research in Applied Sciences and Biotechnology, 1(5), 145-160.

Kumar, S., Keshamma, E., Trivedi, U., Janjua, D., Shaw, P., Kumar, R., ... & Saha, P. (2022). A meta analysis of different herbs (leaves, roots, stems) used in treatment of cancer cells. Journal for Research in Applied Sciences and Biotechnology, 1(3), 92-101.

Butola, K., Bisht, V., & Kumar, R. (2023). Recent Approaches of Ocular Disease and Its Herbal Product Treatment: An Updates. Journal for Research in Applied Sciences and Biotechnology, 2(2), 102-114.

Kohli, A., & Kumar, R. (2023). Role of Antioxidants of Natural Herbs in Management of Male Infertility. Journal for Research in Applied Sciences and Biotechnology, 2(1), 55-80.

Subramanian, M., Keshamma, E., Janjua, D., Kumar, D., Kumar, R., Saha, P., ... & Rao, S. (2022). Quality risk management approach for drug development and its future prospectives. Journal for Research in Applied Sciences and Biotechnology, 1(3), 166-177.

Sultana, A., Singh, M., Kumar, A., Kumar, R., Saha, P., Kumar, R. S., & Kumar, D. (2022). To identify drug-drug interaction in cardiac patients in tertiary care hospitals. Journal for Research in Applied Sciences and Biotechnology, 1(3), 146-152.